Printed from Voxsanity (voxsanity.com.au) — NCT07724106 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.
Back to Ovarian Cancer
Phase 1 Ovarian Cancer Trial, Not Yet Recruiting
NCT07724106
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- Women aged between 18 and 75 years (inclusive) at the time of signing the consent form.
- People with a laboratory-confirmed diagnosis of epithelial ovarian cancer (a specific type of ovarian cancer that starts in the cells covering the ovary) that is classified as Stage II or Stage III according to an internationally recognised staging system.
- People who have undergone surgery to remove as much of the tumour as possible, where laboratory testing of the surgical margins afterwards confirmed a very small amount of microscopic (invisible to the naked eye) tumour remaining at the edge of the removed tissue (1 mm or less).
- People for whom a suitable tumour tissue sample collected during surgery is available for specialised testing — either a fresh sample of at least 100 mg stored immediately in a preserving solution, or at least 5 preserved tissue slices meeting specific quality requirements.
- People whose tumour tissue, when tested with advanced genetic analysis, is found to contain at least 5 usable "neoantigens" — unique markers on cancer cells that meet specific technical thresholds for immune recognition (confirm with trial site).
- People whose post-surgery scan (contrast-enhanced MRI or CT of the pelvis) shows no visible remaining tumour, and where scans confirm the absence of spread to the lungs, liver, or bones.
- People with a general health and activity level rated 0 or 1 on a standard medical scale, meaning they are fully active or able to carry out light activities with no major fatigue or breathlessness, and are expected to live for at least one year.
- People whose blood test results within the 14 days before joining the trial show that the heart, liver, kidneys, thyroid, and blood-clotting system are all functioning within acceptable levels — without having received blood transfusions, growth factors, or certain blood products during that period.
- Women who could potentially become pregnant must have a negative pregnancy blood test before joining, and must agree to use effective contraception (such as condoms or an intrauterine device) from the first dose until six months after the last dose.
- People who are willing and able to follow the trial schedule and whose family members are also willing to support participation, including completing all follow-up visits.
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- People whose ovarian cancer has been confirmed by laboratory testing to be a non-epithelial type, such as germ cell tumours (e.g., teratoma, yolk sac tumour), sex cord-stromal tumours (e.g., granulosa cell tumour), or cancer that has spread to the ovary from another organ such as the gastrointestinal tract.
- People where surgery left behind visible tumour remains, or where post-surgery scans show the cancer has spread to distant parts of the body such as the lungs, liver, or brain, or where the cancer is classified as Stage IV.
- People who have previously received any cancer vaccine treatment (such as a peptide, DNA, or mRNA vaccine targeting cancer), or who have received certain immunotherapy drugs (checkpoint inhibitors such as anti-PD-1 or anti-CTLA-4 antibodies) within 30 days before joining the trial.
- People who experienced serious surgical complications within four weeks after their operation, such as a severe internal infection requiring intravenous antibiotics for seven or more days, a bowel leakage needing further surgery, a major bleed requiring a large transfusion, or a serious bowel blockage requiring prolonged treatment.
- People with an active autoimmune disease (where the immune system attacks the body's own tissues), or a history of such a condition that currently requires ongoing immunosuppressive medication for two weeks or longer — including specific conditions such as rheumatoid arthritis, lupus, ulcerative colitis with a recent flare, multiple sclerosis with a recent relapse, or autoimmune thyroid disease requiring high doses of thyroid hormone.
- People who have had an active infection in the month before joining the trial, including certain bacterial infections (such as pneumonia or kidney infection), specific viral infections (including active hepatitis B or C, HIV, chickenpox, or cytomegalovirus with symptoms), or certain fungal infections (such as pulmonary candidiasis or aspergillosis confirmed by testing).
- People with serious heart, lung, liver, or kidney problems, including: a recent heart attack, unstable chest pain, heart failure, or serious abnormal heart rhythms within the past six months; uncontrolled high blood pressure despite medication; serious lung disease such as a COPD flare-up, pulmonary fibrosis confirmed on scan, or active tuberculosis; significant liver scarring or active liver inflammation; gastrointestinal bleeding within the past year; or kidney failure requiring dialysis or meeting certain threshold levels of poor kidney function.
- People with diabetes that remains poorly controlled despite medication, or thyroid disease (overactive or underactive thyroid) where thyroid hormone levels remain outside the normal range despite treatment.
- People who have a known allergy or sensitivity to any ingredient in the study treatments, including components of mRNA vaccines (such as lipid carriers or the adjuvant poly-ICLC) or anti-PD-1 antibody drugs, or who have previously had a severe allergic reaction (such as anaphylactic shock, throat swelling, or severe breathing difficulty) to similar biological medicines including COVID-19 mRNA vaccines or other antibody-based treatments.
- People who have used immunosuppressive medicines within two weeks before joining the trial — including certain steroids above a specified dose, or drugs such as cyclosporine, tacrolimus, methotrexate, or azathioprine — or who plan to use such medicines during the trial.
- People who have been diagnosed with another cancer (other than ovarian cancer) within the past five years, except for certain cured skin, cervical, or breast conditions that were treated with surgery and have not returned.
- People who are pregnant (confirmed by a blood test) or currently breastfeeding, or women who could become pregnant but are unwilling to use effective contraception throughout the required period.
- People with a psychiatric condition (such as dementia, severe depression, or schizophrenia) or a cognitive difficulty that would prevent them from understanding the trial or reliably attending follow-up.
- People who have taken part in another interventional clinical trial within 30 days before joining this one, or who are still in the follow-up phase of another trial and have not yet completed their final assessment.
- People who are unable or unwilling to provide written consent or to follow the requirements of the trial.
- People whom the trial investigators consider unsuitable for any other reason.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Status
Not Yet Recruiting
Phase
Phase 1
Sponsor
West China Hospital
Registry
ClinicalTrials.gov
Start date
31 July 2026
Est. completion
1 May 2028
Primary endpoints
safety assessment
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.
Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.